Zambon completes transformational acquisition of Breath Therapeutics

Zambon, a privately held long-established Italian multinational company, extends its presence in severe respiratory diseases through the acquisition of Breath Therapeutics, a biopharmaceutical company developing an innovative inhalation therapy for Bronchiolitis Obliterans Syndrome (BOS), a rare fatal respiratory disease currently in phase III. 

• Acquisition reinforces Zambon’s strategy to grow through further globalization and continued investment in Specialty Care. 
• Highly synergistic combination of Breath Therapeutics’ late-stage respiratory drug together with Zambon’s established expertise and commercialization infrastructure. 
• Zambon’s severe respiratory disease business now includes two leading projects in phase III, both with broad geographic outreach, including USA. 
• Price acquisition is €140 million with a total maximum up to €500 million subject to regulatory and sales milestones.

Read More